First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study by Joan Vidal-Jove, Xavier Serres, Eli Vlaisavljevich, Jon Cannata, Alex Duryea, Ryan Miller, Xavier Merino, Manuela Velat, Yossi Kam, Ryan Bolduan, Joseph Amaral, Timothy Hall, Zhen Xu, Fred T. Lee, Timothy J. Ziemlewicz

Get full text

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation by Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles‐Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Maria Vidal, Vicente Peg, Xavier Serres‐Créixams, Graham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T Rubio, Rodrigo Dienstmann, J Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J O'Connor, Orland Díez, Judith Balmaña, Violeta Serra

Get full text